WOW GREAT INFO...here is some more...
CANCER RESEARCH AND BIOSTATISTICS PROGRAMS
The Statistical Center for SWOG, largest of the cooperative groups supported by the National Cancer Institute, is co-located at CRAB. At any one time 100 trials may be active with hundreds more in followup. The results of these trials are central to setting the standard of care for patients in the US and abroad.
CRAB is also the statistical center for the Myeloma Institute of Research and Therapy, a particularly innovative and productive group specializing in the treatment of myeloma.
Our Clinical Trial Services division is built on the decades of experience of our leadership and staff. We offer clinical trials services to research consortia, foundations and pharmaceutical companies. These services tend to focus on under-researched and under-funded cancers such as pancreatic and lung cancer.
CRAB also serves as the statistical center for the SU2C Pancreatic Cancer Dream Team and collaborates closely on the Pancreatic Cancer Research and Therapy clincial trials.
In addition to our own Clinical Trial Consortium for Lung Cancer, CRAB scientists have partnered with the International Association for the Study of Lung Cancer to update and improve the lung cancer staging criteria used world wide.
RECENT SUCCESSES AND CURRENT CHALLENGES
Our leadership in clinical research has helped improve treatment of many cancer types. CRAB assisted in the identification of 70 genes that can predict the prognosis for myeloma patients, guiding better treatment options. In fact, some myeloma patients are living 4 times longer than just 10 years thanks in part to our collaborations with myeloma centers across the country.
As a partner of the International Association for the Study of Lung Cancer, lung cancer staging was developed based on more than 100,000 cases of lung cancer gather from around the world and analyzed by CRAB scientists.
In service to the Stand Up to Cancer Pancreatic Dream Team and Pancreatic Cancer Research Team, CRAB actively participates in the effort to better understand the science behind one of the deadliest cancers.
There is an urgent need to improve surival rates for lung cancer patients. 160,000 people in the United States alone died of lung cancer in 2012. That is why CRAB formed the Clincial Trial Consortium for Lung Cancer (CTC), a collaboration among top-tier lung cancer researchers to better understand lung cancer and identify more effective treatment options. Fighting lung cancer one clinical trial at a time, CRAB uses advancements in the fields of laboratory testing and drug development to find treatments that are safe and effective while considering survival and quality of life. Funding is needed to support this important research.
bull
